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Abstract
Background:  Test results for allergic disease are especially valuable to allergists and family
physicians for clinical evaluation, decisions to treat, and to determine needs for referral.
Methods: This study used a repeated measures design (conjoint analysis) to examine trade offs
among clinical parameters that influence the decision of family physicians to use specific IgE blood
testing as a diagnostic aid for patients suspected of having allergic rhinitis. Data were extracted from
a random sample of 50 family physicians in the Southeastern United States. Physicians evaluated 11
patient profiles containing four clinical parameters: symptom severity (low, medium, high),
symptom length (5, 10, 20 years), family history (both parents, mother, neither), and medication
use (prescribed antihistamines, nasal spray, over-the-counter medications). Decision to
recommend specific IgE testing was elicited as a "yes" or "no" response. Perceived value of specific
IgE blood testing was evaluated according to usefulness as a diagnostic tool compared to skin
testing, and not testing.
Results: The highest odds ratios (OR) associated with decisions to test for allergic rhinitis were
obtained for symptom severity (OR, 12.11; 95%CI, 7.1–20.7) and length of symptoms (OR, 1.46;
95%CI, 0.96–2.2) with family history having significant influence in the decision. A moderately
positive association between testing issues and testing value was revealed (β = 0.624, t = 5.296, p
≤ 0.001) with 39% of the variance explained by the regression model.
Conclusion: The most important parameters considered when testing for allergic rhinitis relate
to symptom severity, length of symptoms, and family history. Family physicians recognize that
specific IgE blood testing is valuable to their practice.
Background
With the prevalence of allergic rhinitis estimated at 21% –
23% for the European population and 20% – 40% for the
western population, appropriate diagnosis and treatment
of allergic rhinitis is of global importance [1,2]. Family
physicians are usually first approached by patients experi-
encing symptoms; however, little information exists
regarding the rationale to perform specific IgE blood test-
ing, which parameters are most important, and the value
of such testing. Given the need to determine if symptoms
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are truly attributed to allergic mechanisms, it is important
that family physicians consider diagnostic testing in con-
junction with a careful examination of patient history,
clinical evidence, and environmental exposure factors to
optimize patient care. The consequences of untreated
symptoms can lead to multiple future complications
while the consequences of misdiagnosis can lead to inap-
propriate treatments [3].
Chronic rhinitis has detrimental effects on quality of life
and work productivity [4,5]. Although medications may
control symptoms in some patients, it is difficult to distin-
guish between allergic rhinitis and non-allergic rhinitis
using clinical evaluation and medication trials. Two com-
monly applied methods are used to uncover an allergic
etiology and identify possible causes. These include skin
prick tests (SPT), and specific IgE tests that are thought to
produce concordant measures on a dichotomous basis for
specificity and sensitivity, as well as a propensity toward
appropriate diagnoses in relation to the presence of spe-
cific IgE antibody levels [6,7]. Decisions to utilize these
tests are influenced by experience, patient history, diag-
nostic accuracy and efficacy of the test, and how well test
results relate to symptoms [8,9].
When presented with patient complaints and bothersome
symptoms that may or may not be related to allergic rhin-
itis, physicians rely on numerous strategies to make an
appropriate diagnosis. How family physicians weigh the
importance of these patient-related parameters when rec-
ommending specific IgE testing is largely unknown, yet
instrumental to determine appropriate treatment and fol-
low-up therapy. To address this research question, we
used a trade off approach (conjoint analysis) to evaluate
family physicians' preference to recommend specific IgE
blood testing with respect to patient symptoms, family
history, and medication use. A second approach using vis-
ual analog scaling (VAS) was added to validate and com-
pare findings obtained from the conjoint analysis. Visual
analog scales have been used extensively in clinical assess-
ment to quantify patient perceptions of disease severity
and the impact of symptoms on health [10,11]. Further
evaluation was performed to determine if family physi-
cians perceive that testing, as part of the care process was
valuable to patient care. As healthcare gatekeepers, family
physicians have the best opportunity to construct a base-
line assessment of these patients to determine if current
treatment strategies are effective, or if patients would ben-
efit from a referral to an allergist or other specialist.
Methods
Study sample
Primary care (family) physicians in a southeastern state in
the United States were identified through already estab-
lished medical societies and physician mailing lists that
were complied at the Recruitment and Retention Shared
Facility at the University of Alabama, Birmingham. Mail-
ing addresses, telephone numbers, fax numbers, specialty
area, and practice affiliation was verified for 424 physi-
cians in Alabama. From the list of 424 physicians, a sam-
ple of 150 physicians was randomly selected to participate
in the study. Three separate mailings containing 50 ques-
tionnaires were sent by priority mail, one week apart to
these physicians at their respective practice sites. The ques-
tionnaire package contained a letter of invitation to partic-
ipate in the study, along with a self-addressed stamped
envelope for the returned questionnaire. Thirty-two ques-
tionnaires were completed and returned during the first
month, follow-up reminder calls were conducted three
weeks after the initial mailing (77 calls were answered),
and 14 surveys were faxed per request by providers. A total
of fifty completed surveys were returned within two
months. The estimated sample size of 50 was determined
for this study following examples for studies with
repeated-measures designs [12]. As an incentive, a gift cer-
tificate for a local department store was mailed to physi-
cians who completed the questionnaire.
Instrument Development
Techniques to evaluate preference include standard gam-
ble, alternate rating (e.g., visual analog) scale, and time
trade-off [13]. Besides these techniques, conjoint analysis
(a trade off approach among attributes) is another tech-
nique that is used to evaluate the importance of prefer-
ence measurements [14]. Choices are usually presented in
the form of profiles that are ranked or rated (e.g., recom-
mend specific IgE testing – yes or no). The part-worth val-
ues (coefficients) for each attribute are obtained from the
random effects logistic regression model analysis with
repeated measures (50 responses × 9 profiles = 450 obser-
vations), which follows stated choice experiments based
on choice theory [15,16]. Although developed in market-
ing research, the use of conjoint analysis in health care is
becoming a valuable tool [17-20].
In an attempt to simplify the conjoint exercise for this
study, each attribute was assigned three levels (see Addi-
tional file 1). For example, symptom severity was assigned
"high," "medium," or "low," and symptom length
appeared as symptoms for "less than 5 years," "symptoms
for 10 years," and "symptoms for more than 20 years."
Family history included "neither parent has allergic rhini-
tis," "mother has allergic rhinitis," and "both parents have
allergic rhinitis." Medication use included the use of
"over-the-counter medications to control allergy symp-
toms," "prescribed antihistamines," and the "prescribed
nasal spray to control allergy symptoms." Effects coding
was used to construct the numerical values of the profile
attributes. The "low" level was the reference value and was
denoted as -1. The "high" level was denoted as +1.BMC Family Practice 2008, 9:47 http://www.biomedcentral.com/1471-2296/9/47
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A one-third fractional factorial design using repeated
measures was chosen to minimize the number of profiles
to 9 thereby attempting to avoid respondent fatigue. Two
additional profiles were produced manually as holdout
profiles for use in validation [21]. Each profile portrayed
an individual with a pre-determined set of allergic symp-
toms and clinical indicators. For the dependent variable,
family physicians were asked to provide a "yes" or "no"
response to whether they would recommend specific IgE
blood testing for this patient. For the purposes of this
study, which specific IgE blood test was used by family
physicians was not important, or what type of test (food
or inhalant) was performed.
The hypothesis for this study was that the estimated part-
worth values or coefficients, exponentiated to odds ratios
in this study, for each of the four profile attributes were
simultaneously equal to zero. In the next section, family
physicians were asked to indicate if recommendations to
test were influenced by managed care guidelines, value of
testing, referral activities, familiarity with specific IgE test-
ing, relation of test results to symptoms, and value of test
to practice, the likelihood to use specific IgE testing using
a ten-point scale "less likely to test" to "more likely to
test." Specific IgE blood testing was rated using a scale ('1'
= not valuable to '6' highly valuable) for overall value,
value compared to skin testing, and value compared to
not testing at all. Demographic characteristics of partici-
pating family physicians, such as age, gender, years in
practice, and practice site information, were elicited in the
last section of the questionnaire. To assess questionnaire
validity, participants provided an estimate of a patient's
overall health status given the impact of various symp-
toms and clinical indicators with 0 being the "Worst Pos-
sible State" and 100 being the "Best Possible State." The
means for these items were compared to those rankings
obtained from the conjoint exercise to offer additional
information regarding testing.
Data analysis
Descriptive statistics were provided for demographic vari-
ables. The conjoint exercise data were analyzed using a
random effects logistic regression model. This type of
model was chosen since it produces standard errors that
account for the intra-individual correlation. Assumptions
of normality, linearity, and equal variances among the
items were evaluated to ensure appropriate interpretation
of statistical analyses. All statistical analyses were per-
formed using Stata/SE version 9 (College Station, Texas,
USA). An Institutional Review Board from the University
of Alabama, Birmingham, granted approval for the study.
Results
Demographics
Participating physicians (33% response rate) were more
likely to be male, between 40 and 60 years of age and with
about 20 years of clinical experience in a private practice
setting (Table 1). Independent t-test revealed that among
older physicians (> 50 years), those with 10 or more years
in practice placed a greater value on specific IgE testing
than not testing (n = 32; mean = 4.6) compared to those
with less than 10 years in practice (n = 18; mean = 3.8; t =
2.2; P = 0.03).
Conjoint model
Results from the random effects logistic regression model
are presented in Table 2. The interaction between study
attributes and demographic characteristics was not signif-
icant. Attributes, that are more likely to influence decision
to request specific IgE blood testing, were symptom sever-
ity, length of time having symptoms, and history for aller-
gic rhinitis reported for both parents. Results reveal the
log likelihood = -196.983, Wald χ2 = 94.03, P < 0.0001,
with 448 observations for 50 physicians each physician
evaluating 9 profiles, thus supporting the hypothesis that
the impact of parameters on specific IgE blood testing are
not perceived equally. Symptom severity had the greatest
impact on physician decisions to test patients for allergic
rhinitis (OR, 12.11; 95%CI, 7.1–20.7). Thus, one would
expect that physicians would be 12 times more likely to
consider the specific IgE blood test for patients with high
symptom severity compared to patients with low symp-
tom severity. Although not significant, other attributes
such as length of symptoms and both parents having a
history of allergic rhinitis influenced physician decisions
to test (OR, 1.46; 95%CI, 0.96–2.2: OR, 1.44; CI, 0.95–
2.2, respectively). However, some physicians may not be
willing to trade among the alternatives when the decision
involved a potentially dominant attribute, where symp-
tom severity may be the only reason to recommend spe-
cific IgE blood testing. To assess the potentially dominant
effect of symptom severity [22], two versions of the model
were run – one containing profiles where symptom sever-
Table 1: Demographic Characteristics of Family Physicians
Characteristic Value (n = 50)
Age, y
Mean (SD) 49 (12.0)
Range 29 – 79
Years in Practice
Mean (SD) 18.6 (12.4)
Range 2 – 52
Gender, no. (%)
Male 35 (71.4)
Female 14 (28.6)
Practice type, no. (%)
Private/Independent 43 (87.8)
Managed care setting 6 (12.2)BMC Family Practice 2008, 9:47 http://www.biomedcentral.com/1471-2296/9/47
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ity was present and one containing only those where
symptom severity was absent (results not shown). In both
situations, other parameter estimates were significant
indicating the hypothesis that coefficients were simulta-
neously equal to zero was rejected regardless of the pres-
ence of the symptom severity.
Validation
Two methods were used to validate the results of the con-
joint exercise – the use of a holdout profile and an alter-
nate rating method. First, was to estimate predictive
validity for the holdout profile using the regression model
developed from the 9 orthogonal profiles. The relation
between the observed response for the holdout profiles
and the predicted responses was then examined. The pre-
dicted values for the holdout profiles were quite similar to
the observed value. The predicted mean probabilities were
82.7% and 78.4% compared to the observed values 70%
and 78%, respectively. The differences were not signifi-
cantly different (t-test; p = 0.162, p = 0.996, respectively)
suggesting that the conjoint model exhibits acceptable
internal predictive validity. Second, was the use of a VAS
where participants responded to each item from the con-
joint study presented separately. Lower mean scores
obtained for each domain indicated that the particular
domain represented choices that were less desirable to the
respondent. Symptom severity (mean = 36.7; SD = 16.4)
and symptom length (mean – 36.0; SD = 16.6) were
ranked the worst followed by medication use (52.6; SD =
21.5), and family history (mean = 61.0; SD = 24.0),
revealing consistent response patterns between the con-
joint study and the VAS.
Impact of testing issues on value
Kaiser-Meyer-Olkin measure of sampling adequacy for the
final principal components analysis was 0.82 and the sig-
nificant (p ≤ 0.001) Bartlett test of sphericity supported
the use of factor analysis for the items used to assess test-
ing issues [23]. One factor was retained for testing issues
accounting for 54.6% of the variance. Two items, diffi-
culty in interpreting test results and insurance coverage
were dropped from the analysis. The factor structure was
further verified by reanalyzing the reliability of the dimen-
sion. Descriptive statistics (item's mean and standard
deviation) and Cronbach's alpha for study items are pre-
sented in Table 3. Most noteworthy, was that physicians
perceived that "how well the test correlated with symp-
toms" was given the highest score (mean = 7.6; SD = 1.9)
with respect to "more likely to use specific IgE testing." In
addition, physicians perceived that specific IgE testing had
significant (p ≤ 0.007) value overall, perceived value com-
pared to not testing, and perceived value was comparable
to skin testing. Cronbach's alpha for the remaining nine
items for testing issues was 0.90 and 0.86 for the three
items consisting of testing value, indicating a high degree
of internal consistency or a high signal-to-noise ratio (i.e.,
error variance minimized) across individuals [24].
Linear regression analysis was used to assess the relation-
ship between testing issues and testing value. As hypothe-
sized, results using composite scores for testing issues and
testing value revealed a moderately positive association
between these two dimensions (β = 0.624, t = 5.296, p ≤
0.001) with (R2 = 0.39) 39% of the variance explained by
the model.
Discussion
According to our results, family physicians consider symp-
tom severity to be the significant determinant, followed
by symptom length and family history when recommend-
ing the use of specific IgE blood testing for patients sus-
pected of having allergic rhinitis. Physicians in practice for
Table 2: Results from the random effects logistic regression model
Attribute Level Odds Ratio P-value 95% CI
Symptom severity High 12.11 <0.001a [7.1, 20.7]
Medium 1.46 0.281 [0.84, 1.9]
Low* 0.06
Length of symptoms >20 years 1.46 0.073b [0.96, 2.2]
5 years to 20 years 1.39 0.074b [0.96, 2.2]
<5 years* 0.47
History of allergic rhinitis Both parents 1.44 0.089b [0.95, 2.2]
Mother only 1.20 0.37 [0.80, 1.8]
Neither parent* 0.58
Medication use Intranasal corticosteroids 1.12 0.586 [0.75, 1.7]
Prescribed antihistamines 1.33 0.171 [0.89, 2.0]
OTC allergy medications* 0.67
*Baseline attribute level
a p < 0.05; b p < 0.10
Log likelihood = -196.983; Wald Chi square = 94.03; p < 0.0001
448 observations for 50 individualsBMC Family Practice 2008, 9:47 http://www.biomedcentral.com/1471-2296/9/47
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10 years or more placed greater value on specific IgE test-
ing compared to those in practice for less than ten years.
Moreover, results from VAS were consistent with findings
from the conjoint study. Our findings were also corrobo-
rated in another recent study where VAS for symptom
severity compared favorably with standard quality of life
measures [25].
Professional organizations such as the American Academy
of Allergy, Asthma, and Immunology and the European
Academy of Allergology and Clinical Immunology recog-
nize that allergic disease is a major health concern often
requiring specific allergen avoidance and treatment strate-
gies that are based on positive findings from history and
diagnostic testing [26,27]. Results from this study support
the positions elicited from the Joint Task Force on Practice
Parameters for Rhinitis and Allergic Rhinitis and its
Impact on Asthma (ARIA) in that family physicians are
capable of recommending specific IgE testing, using the
test to confirm allergic disease and identifying possible
allergens [28-30]. Also consistent with recommendations
from the Joint Task Force, results from the VAS closely
approximated the findings of the conjoint study, thus
revealing the usefulness of VAS in clinical practice to
assess symptom severity for patients suspected of having
allergic rhinitis.
Values for each item relating to patient perceptions of the
test, patient demand to have testing performed, other clin-
ical indicators, and the type of allergic rhinitis were sum-
mated to create a composite score. This composite score
for testing issues yielded a moderately positive correlation
with testing value, thus providing initial evidence that
issues associated with testing and the process of care were
linked to outcomes such as testing value. Moreover, posi-
tively framing the information describing the benefits of
testing and the value of testing to patients is also known
to influence their expectations of benefits [31].
Limitations include a low response rate and a cross-sec-
tional study representing one geographical region. In
addition, family physicians may consider attributes that
were not evaluated in this study when deciding to request
specific IgE blood testing for patients suspected of having
allergic rhinitis. Hypothetical profiles were developed for
this study and may not include all aspects of information
provided by patients to family physicians, reflect what
happens in actual clinical practice, and represent the opin-
ions of physicians in other geographical areas.
Given the economic burden of allergic rhinitis on society
and the research evidence that supports an inverse rela-
tionship between health status and specific IgE antibody
levels [32-34], current guidelines should be repositioned
and possibly modified to allow family physicians to have
a more active role in specific IgE blood testing. Although
ARIA suggests the SPT as a first line choice when further
evaluation of patients is needed, interpretation of test
results requires extensive training and experience. Thus,
specific IgE testing was examined in this study as a practi-
cal choice for primary care physicians. As suggested from
this study and supported in the literature, with proper
training family physicians would become more adept at
quantifying the results from specific IgE blood testing and
recognizing when to refer patients (e.g., continued treat-
ment failure, complications, and beyond scope of exper-
tise) to allergists or other specialists [35-38]. Another
important aspect of training is the need to consider spe-
cific IgE blood test and SPT results in the context of patient
history, especially when discrepancy exists between test
results and symptoms. Diagnostic testing, per se, is no sub-
stitute for a thorough examination of patient symptoms,
Table 3: Descriptive Statistics and Scale Evaluation for Issues and Test Value
Mean (SD)
Testing issues *
Managed care practice guidelines 5.4 (2.3)
Patient's perceived value of the test 6.5 (1.9)
Reduced need to refer patients to allergists 6.8 (2.0)
Difficulty in interpreting test results 4.4 (2.6)
Familiarity with test use 6.9 (2.3)
Patient demand to have the test done 7.0 (1.9)
Type of allergic rhinitis (intermittent vs. persistent) 6.6 (1.9)
How well test results relate to symptoms 7.6 (1.9)
Value of testing to my practice 6.9 (2.3)
Testing value **
Overall value of specific IgE as a diagnostic tool 3.9 (1.1)
Compared to skin testing, usefulness of specific IgE blood testing 3.9 (1.4)
Compared to not testing at all, usefulness of specific IgE blood testing 4.3 (1.2)
* Issues – scale = 1 less likely to test, 10 = more likely to test; (measure of internal consistency of items – α = 0.90)
** Value – scale = 1 not valuable; 6 = highly valuable; (measure of internal consistency of items – α = 0.86)BMC Family Practice 2008, 9:47 http://www.biomedcentral.com/1471-2296/9/47
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health status, and medical history. In summary, allergists
and family physicians understand that test results coupled
with the findings of a careful clinical examination serve as
the foundation to establish a strategy for treatment, from
which future health outcomes can be evaluated to deter-
mine the success of treatment.
Conclusion
Family physicians rely on symptom severity, and to some
extent on length of time that symptoms are present and
family history to determine whether patients should be
tested to determine the presence of allergic disease. Physi-
cians with more practice experience placed greater value
on specific IgE testing. Findings also revealed a moder-
ately positive association between the issues influencing
the use of specific IgE blood testing and test value. Over-
all, family physicians valued specific IgE blood testing,
especially compared to not testing.
From the study findings, family physicians can use symp-
tom severity as a gauge in clinical practice to determine if
patients should undergo detection and testing for allergic
rhinitis or related conditions perhaps much earlier during
the process of clinical evaluation, especially in the pres-
ence of severe symptoms and a positive family history.
Baseline evaluation will also increase the likelihood of
determining the correct diagnosis and appropriate treat-
ment, and to ascertain the need for referral. Future
research is needed to address the impact of patient expec-
tations and treatment experience on value and other out-
come measures.
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